Sage Journals: Discover world-class research

Abstract

The effects of sublingual fentanyl citrate (SLFC) were assessed in 11 hospice inpatients with cancer-related breakthrough pain. Patients were asked to rate their pain, using a visual analogue scale, before SLFC, then after 3, 5, 10, 15, 30, 45 and 60 min. Six patients (55%) had reductions in pain scores at 10 min and nine patients (82%) at 15 min. Ratings for SLFC were very good (18%), good (36%), moderate (28%), and bad (18%). Compared to the usual breakthrough medication, SLFC was better (46%), the same (36%), or worse (18%). Advantages of SLFC included ease of use, quick onset of action and no associated drowsiness. No systemic adverse events were noted, but two patients reported dry mouth and two a bitter taste. Two patients found it difficult to retain the medication under the tongue. Seven patients (64%) said they would continue to use SLFC. Sublingual fentanyl citrate appears safe and well tolerated by these patients. Randomized placebo-controlled and dose ranging studies are required to confirm these findings.

Keywords

fentanyl citrate sublingual drugs cancer breakthrough pain

Get full access to this article

View all access options for this article.

References

Harris D , Robinson JR . Drug delivery via mucous membranes of the oral cavity. J Pharm Sci 1992; 81: 1–10.

Weinberg DS , Inturrisi CE , Reidenberg B et al. Sublingual absorption of selected opioids. Clin Pharmacol Ther 1988; 44: 335–342.

Hanks G , Portenoy RK , MacDonald N , Forbes K . Difficult pain problems. In: Doyle D , Hanks GWC , MacDonald N eds. Oxford textbook of palliative medicine, 2nd edn. Oxford: Oxford University Press 1998: 454–477.

Portenoy RK , Payne R , Coluzzi P et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79: 303–312.

Zeppetella G . Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med 2000; 14: 57–58.

Portenoy RK , Hagen NA . Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273–281.

Portenoy RK . Cancer pain: pathophysiology and syndromes. Lancet 1992; 339: 1026–1031.

Fine PG , Busch MA . Characterisation of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998; 16: 179–183.

Portenoy RK , Payne D , Jacobsen P . Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129–134.

10.

Petzke F , Radbruch L , Zech D , Loick G , Grond S . Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage 1999; 17: 391–401.

11.

Zeppetella G , O'Doherty C , Collins S . Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000; 20: 87–92.

12.

Coluzzi PH . Sublingual morphine: efficacy reviewed. J Pain Symptom Manage 1998; 16: 184–192.

13.

Worsley MH , MacLeod AD , Brodie MJ , Asbury AJ , Clark C . Inhaled fentanyl as a method of analgesia. Anaesthesia 1990;45: 449–451.

14.

Streisand JB , Varvel JR , Stanski DR et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anaesthesiology 1991; 75: 223–229.

15.

Striebel HW , Krämer J , Luhmann I , Rohierse-Hohler I , Rieger A . Pharmakokinetische studie zur intranasalen gabe von fentanyl. Dr Schmerz 1993; 7: 122–125.

16.

Expert Working Party of the European Association for Palliative Care . Morphine in cancer pain: modes of administration. Br Med J 1996; 312: 823–826.

17.

Watson NW , Taylor KM , Joel SP , Slevin ML , Eden OB . A pharmacokinetic study of sublingual aerosolised morphine in healthy volunteers. J Pharm Pharmacol 1996; 48: 1256–1259.

18.

Kunz KM , Theisen JA , Schroeder ME . Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage 1993; 8: 189–190.